Tetraphase Pharmaceuticals (NASDAQ:TTPH) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.
According to Zacks, “Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company’s product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts. “
Several other research firms also recently weighed in on TTPH. HC Wainwright raised their price objective on Tetraphase Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Monday, November 6th. ValuEngine downgraded Tetraphase Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. BMO Capital Markets raised their price objective on Tetraphase Pharmaceuticals from $13.00 to $24.00 and gave the company an “outperform” rating in a research note on Wednesday, October 4th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $13.00 price objective on shares of Tetraphase Pharmaceuticals in a research note on Tuesday, September 12th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Tetraphase Pharmaceuticals in a research note on Sunday, September 17th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $15.15.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) EPS for the quarter, meeting the consensus estimate of ($0.63). Tetraphase Pharmaceuticals had a negative return on equity of 88.27% and a negative net margin of 1,382.33%. The business had revenue of $4.10 million during the quarter, compared to analysts’ expectations of $1.59 million. During the same period last year, the firm earned ($0.58) EPS. The company’s quarterly revenue was up 355.6% compared to the same quarter last year. research analysts anticipate that Tetraphase Pharmaceuticals will post -2.88 EPS for the current year.
In other Tetraphase Pharmaceuticals news, insider Jacques Dumas sold 8,750 shares of the firm’s stock in a transaction on Tuesday, October 31st. The stock was sold at an average price of $6.03, for a total transaction of $52,762.50. Following the completion of the transaction, the insider now owns 8,750 shares of the company’s stock, valued at $52,762.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director L Patrick Gage purchased 3,880 shares of the company’s stock in a transaction on Wednesday, November 29th. The shares were bought at an average cost of $6.45 per share, with a total value of $25,026.00. Following the transaction, the director now directly owns 38,880 shares of the company’s stock, valued at approximately $250,776. The disclosure for this purchase can be found here. Company insiders own 5.50% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in TTPH. SG Americas Securities LLC purchased a new position in Tetraphase Pharmaceuticals during the third quarter worth $107,000. Brighton Jones LLC purchased a new position in Tetraphase Pharmaceuticals during the third quarter worth $108,000. AXA purchased a new position in Tetraphase Pharmaceuticals during the second quarter worth $132,000. Virtu KCG Holdings LLC purchased a new position in Tetraphase Pharmaceuticals during the second quarter worth $147,000. Finally, Voya Investment Management LLC increased its position in Tetraphase Pharmaceuticals by 17.8% during the second quarter. Voya Investment Management LLC now owns 20,583 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 3,104 shares in the last quarter. 58.15% of the stock is owned by institutional investors.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.